Our results indicate that high expression of BCL2L2 leads to resistance to Lenvatinib and that downregulation of this protein may increase HCC sensitivity to Lenvatinib in vivo and in vitro, which agrees with a previous study showing that Bcl-2 can effectively curb ovarian cancer cell apoptosis through resistance to cisplatin [33]. The gene discussed is BCL2L2; the disease is ovarian carcinoma.